Short Interest in Bonk, Inc. (NASDAQ:BNKK) Decreases By 36.6%

Bonk, Inc. (NASDAQ:BNKK) was the target of a large decline in short interest during the month of July. As of July 31st, there was short interest totaling 193,599 shares, a decline of 36.6% from the July 15th total of 305,481 shares. Currently, 5.0% of the shares of the stock are short sold. Based on an average trading volume of 58,461 shares, the days-to-cover ratio is currently 3.3 days.

Bonk Price Performance

Bonk stock traded down $0.03 during midday trading on Tuesday, reaching $0.94. The stock had a trading volume of 130,863 shares, compared to its average volume of 699,401. Bonk has a twelve month low of $0.91 and a twelve month high of $21.20. The firm has a market cap of $7.53 million, a price-to-earnings ratio of -0.25 and a beta of 1.99. The firm’s fifty day simple moving average is $1.26 and its two-hundred day simple moving average is $2.29.

Bonk (NASDAQ:BNKK) last announced its earnings results on Friday, August 14th. The company reported ($0.76) earnings per share (EPS) for the quarter. The firm had revenue of $1.16 million for the quarter. Bonk had a negative net margin of 952.21% and a negative return on equity of 122.84%.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of BNKK. BlackRock Inc. acquired a new stake in Bonk during the 2nd quarter worth about $50,000. State Street Corp acquired a new position in shares of Bonk in the 4th quarter valued at about $33,000. Jane Street Group LLC purchased a new stake in shares of Bonk in the fourth quarter worth approximately $96,000. Steward Partners Investment Advisory LLC purchased a new stake in shares of Bonk in the fourth quarter worth approximately $37,000. Finally, Geode Capital Management LLC acquired a new stake in shares of Bonk during the fourth quarter worth approximately $128,000. 12.55% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages have recently commented on BNKK. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Bonk in a report on Friday, July 24th. Wall Street Zen raised Bonk from a “sell” rating to a “hold” rating in a research note on Saturday, July 4th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, Bonk has a consensus rating of “Sell”.

About Bonk

Safety Shot, Inc, a wellness and functional beverage company, engages in the research and development of over-the-counter products and intellectual property. Its products pipeline includes Photocil to address psoriasis and vitiligo; JW-700 to treat hair loss; JW-500 for women’s sexual wellness; NoStingz, a jellyfish sting prevention sunscreen; and JW-110 for the treatment of atopic dermatitis/eczema. The company primarily sell its products through third-party physical retail stores and partners. The company was formerly known as Jupiter Wellness, Inc and changed its name to Safety Shot, Inc in September 2023.